Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The 10-Ks have been audited by Warren Averett, LLC since 2007.
I use MRNA as an easy example
The ex-pharma exec leading Trump's COVID-19 vaccine program has $10 million in stock options for a company getting federal funding
I've made a lot of money for a lot of people.
and yet so little buying of the stock.
What does that have to do with this company that is yet to have any product for Covid?
Technicals don't take into account catalysts and biotechs are catalyst driven. Within just the next month or two Cytodyn has a large list of catalysts coming down and your technicals will be shown to be useless.
What do you see?
I just don't see it worth the effort to own them
But you promised us $1.60, now I'm disappointed.
Lawsuits by the 5 firms weren't dropped, they never existed.
Thus far the "scientific data" hasn't proved itself.
Charts tell what investors are doing
Can I prove it? No. Why? Because it's a lie.
FDA has approved Leronlimab for H.I.V. combo therapy
Emergency Use Approval is not based on a standard BLA timeline.
74 days to either accept or reject. Once interim COVID-19 trial results are released and the spotlight is on Cytodyn, HIV BLA rejection without extremely good cause would blow up in the FDA's face. The last thing the FDA wants is an investigation into how the FDA held back a no SAE, no resistance HIV drug for years.
The moment the FDA accepts the BLA filing for HIV they're stuck. If they deny approval it goes in front of an independent review board.
All of the 'science will rule out' bluster on these boards means nothing if these corrupt deep staters are going to screw cydy, and in my judgement, they are well on their way to doing just that.
Finally, shareholders have no say in deciding a reverse split or any kind of a split. If the company desires it, they can do it. In the same way they can increase authorized shares or dilute by issuing them.
I think there's a distinct possibility that stocks go up and down.
I've been concerned that CYDY will have to continuously chase patent infringement for "mimic" drug development due to the expected success of PRO 140/Leronlimab.
Phantom shares are naked shorts that are never covered, still exist in the system and can artificially and unofficially inflate the O/S.
https://www.thekomisarscoop.com/2020/03/how-phantom-shares-on-wall-street-threaten-u-s-companies-and-investors/
Legal Naked shorting briefly by MMs is a normal part of their job processing orders for thinly traded stocks
Naked shorting often occurs because of lack of shares or cost to borrow shares. Cytodyn has hit both in recent months. It doesn't look like a large number of naked shorts are occurring with Cytodyn but it wouldn't surprise me if a few brokerages are offering naked shorts to keep that extra borrow cost for themselves.
Failure to deliver for Cytodyn stock in April 2020 - 18,197.444 shares.
https://www.sec.gov/data/foiadocsfailsdatahtm
Did QAnon tell you so?
No registered and regulated broker will let anybody "naked short
Finra fines Interactive Brokers $5.5 million for short-sale violations
Both of the above events were due to transpire today correct?
A conspiracy theorist covering for another conspiracy theorist is quite circular but par for the course in that milieu.
Just fine.
Spot on! I keep running into new ones to check. Latest addition for the list - Alopecia Areata.
Why would you omit that we're going head to head against remdesivir?
I'll let you in on a little secret the FDA approves drugs not CEOs.
Do you really think that the actual approval will come in 2 months?
COVID-19 approval within two months sets everything right.
IF FAUCI HAD NOT DESIGNATED REMDESIVIR AS OUR SAVIOR.
I’m so confused if the results are as good as we think they are doesn’t the FDA have an ethical obligation to stop the trials and approve the drug.
The rationale is that of the greater good. A few people could be helped now under compassionate use but it would slow down trial enrollment. Many more could be helped if this was widely commercially available. It does bode well for fast FDA approval on interim data.